Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 376 to 390 of 729 results for diabet*

  1. Self-monitoring of blood glucose levels: What is the optimal frequency for self‑monitoring of blood glucose in adults with type 2 diabetes?

    optimal frequency for self‑monitoring of blood glucose in adults with type 2 diabetes? Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    16 December 2021

  2. The use of C-peptide in diagnosing diabetes: What is the effectiveness of C‑peptide at correcting misclassification of diabetes diagnosis and what is the optimal timing for the test in distinguishing subtypes of diabetes?

    use of C-peptide in diagnosing diabetes: What is the effectiveness of C‑peptide at correcting misclassification of diabetes...

    Research recommendation
    Published
    11 April 2022

  3. What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with type 1 diabetes?

    treatment in people with type 1 diabetes? Any explanatory notes(if applicable) People with type 1 diabetes have increased...

    Research recommendation
    Published
    9 June 2015

  4. Long-term outcomes of bariatric surgery on people with type 2 diabetes: What is the long-term effect of bariatric surgery on diabetes-related complications and quality of life in people with type 2 diabetes compared with optimal medical treatment?

    type 2 diabetes: What is the long-term effect of bariatric surgery on diabetes-related complications and quality of life in...

    Research recommendation
    Published
    30 September 2022

  5. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)

    Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.

    Technology appraisal guidance
    Published
    24 July 2024
    View recommendations

    Sections for TA988

  6. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

    Technology appraisal guidance
    Last updated
    1 May 2025
    View recommendations

    Sections for TA878

  7. How can fetuses at risk of intrauterine death be identified in women with diabetes?

    How can fetuses at risk of intrauterine death be identified in women with diabetes? Any explanatory notes(if applicable) Unexpected...

    Research recommendation
    Published
    9 June 2015

  8. How effective and cost effective are interventions which use either a 'total population' or 'high-risk population' approach to preventing type 2 diabetes among people from black and minority ethnic or lower socioeconomic groups?

    'total population' or 'high-risk population' approach to preventing type 2 diabetes among people from black and minority ethnic or lower...

    Research recommendation
    Published
    9 June 2015

  9. Effectiveness of SGLT2 inhibitors for different ethnic groups: What is the clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes and chronic kidney disease, stratified across different ethnic groups?

    clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes and chronic kidney disease, stratified across...

    Research recommendation
    Published
    24 March 2022

  10. Effectiveness of SGLT2 inhibitors for adults with a urine ACR below 3 mg/mmol: What is the clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes, chronic kidney disease and a urine ACR of less than 3 mg/mmol?

    clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes, chronic kidney disease and a urine ACR of less than...

    Research recommendation
    Published
    24 March 2022

  11. Continuous glucose monitoring in children and young people with type 2 diabetes: What is the effectiveness and cost effectiveness of continuous glucose monitoring devices in children and young people with type 2 diabetes?

    Continuous glucose monitoring in children and young people with type 2 diabetes: What is the effectiveness and cost effectiveness of...

    Research recommendation
    Published
    8 April 2022

  12. The effects of stopping and/or switching drug treatments to control blood glucose levels: In adults with type 2 diabetes, what are the effects of stopping and/or switching drug treatments to control blood glucose levels, and what criteria should inform the decision?

    drug treatments to control blood glucose levels: In adults with type 2 diabetes, what are the effects of stopping and/or switching drug...

    Research recommendation
    Published
    16 December 2021

  13. Long-term outcomes associated with blood glucose lowering agents: In adults with type 2 diabetes, what are the long‑term effects of blood glucose lowering therapies such as dipeptidyl peptidase‑4 (DPP‑4) inhibitors, sodium–glucose cotransporter‑2 (SGLT2) inhibitors and meglitinides?

    outcomes associated with blood glucose lowering agents: In adults with type 2 diabetes, what are the long‑term effects of blood glucose...

    Research recommendation
    Published
    16 December 2021

  14. Non-metformin-based drug treatment combinations to control blood glucose levels: In adults with type 2 diabetes, what treatment combinations (for example, glucagon‑like peptide‑1 [GLP‑1] mimetics and insulin combination therapy with meglitinides) are most effective when initial drug treatment with non‑metformin monotherapy fails to adequately control blood glucose levels?

    treatment combinations to control blood glucose levels: In adults with type 2 diabetes, what treatment combinations (for example,...

    Research recommendation
    Published
    16 December 2021

  15. Further research is recommended to resolve uncertainties about the cost effectiveness of fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema. This should focus on a group of patients whose condition is unresponsive to other available therapies, and include measures of efficacy and health-related quality of life. Research should focus on identifying appropriate utility values, taking into account the utility values for different levels of visual acuity and the relative relationship in utility values from treating the best-seeing and the worse-seeing eye. The appropriateness of generalising utility values from one group of eye conditions to another group would also be of value.

    fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema. This should focus on a group of...

    Research recommendation
    Published
    9 June 2015